Reference : Comparative Pharmacokinetics of Two Intravenous Administration Regimens of Tiludronat...
Scientific journals : Article
Life sciences : Veterinary medicine & animal health
Comparative Pharmacokinetics of Two Intravenous Administration Regimens of Tiludronate in Healthy Adult Horses and Effects on the Bone Resorption Marker Ctx-1
Delguste, Catherine mailto [Université de Liège - ULiège > Département de sciences fonctionnelles > Pharmacologie, pharmacothérapie et toxicologie >]
Amory, Hélène mailto [Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Médecine interne des équidés >]
Guyonnet, J. [> > > >]
Thibaud, D. [> > > >]
Garnero, P. [> > > >]
Detilleux, Johann mailto [Université de Liège - ULiège > Département de productions animales > Génétique quantitative >]
Lepage, O. M. [> > > >]
Doucet, Michèle [Université de Montréal - UdeM > Biomédecine > > >]
Journal of Veterinary Pharmacology and Therapeutics
Blackwell Publishing
Yes (verified by ORBi)
[en] horses ; bisphosphonates ; bone metabolism ; biomarkers ; pharmacology
[en] Bioavailability and pharmacological effects of tiludronate were compared when administered as an intravenous (i.v.) bolus at a dosage of 0.1 mg/kg body weight (b.w.) once daily for 10 consecutive days (group 1, n = 6) and as a single constant rate infusion (CRI) at a total dose of 1 mg/kg b.w. (group 2, n = 6) in healthy adult horses. Tiludronate and carboxy-terminal cross-linking telopeptide of type I collagen (CTX-1) were measured in plasma and urine. There was no statistically significant difference in area under the curve (AUC) and clearance (Cl) between the two groups. Bioavailability of the CRI was 103% (not significantly different) that of the 10 daily i.v. bolus doses. Cumulative urine tiludronate excretion could not be compared between groups because of poor sensitivity of the assay in urine. Plasma and urine CTX-1 levels were not different between groups throughout the study. However, interindividual variations were greater in group 1 than in group 2. A significant decrease in CTX-1 levels was observed in plasma after the first administration in group 1, but not in urine; while in group 2, a significant decrease in CTX-1 concentrations was observed after treatment in both plasma and urine. In conclusion, both dosage regimens of tiludronate produced similar plasma exposure and pharmacological effects in adult healthy horses.
CEVA Santé Animale
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
jvp_936_doi.pdfPublisher postprint180.37 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.